Filing Flows › Twist Bioscience (TWST) › Q3 FY26 › vs Q2 FY26
Twist Bioscience (TWST) Q3 FY26 vs Q2 FY26 (quarter over quarter)
Twist Bioscience's revenue rose $7.7M (+7%) from $111M in Q2 FY26 to $118M in Q3 FY26. The biggest changes: NGS applications +$4.4M (+8%); DNA synthesis and protein solutions +$3.3M (+6%).
Twist Bioscience, Q3 FY26: revenue $118M (+23% year over year), operating margin -30.6%, net loss $35.1M, operating cash flow $1.1M. The chart draws each line against Q2 FY26, the increases inside each band.
Every line
| Line | Q3 FY26 | Q2 FY26 | Change | % |
|---|---|---|---|---|
| NGS applications | $61.8M | $57.4M | $4.4M | +8% |
| DNA synthesis and protein solutions | $56.6M | $53.3M | $3.3M | +6% |
| Revenue | $118M | $111M | $7.7M | +7% |
| Other income, net | $1.5M | $1.9M | −$345K | -18% |
| Net loss | $35.1M | $44.0M | −$9.0M | -20% |
| Costs & expenses | $155M | $157M | −$1.7M | -1% |
| Operating costs | $155M | $157M | −$1.9M | -1% |
| Income tax | $311K | $43K | $268K | +623% |
| Cost of revenue | $55.9M | $53.6M | $2.3M | +4% |
| Research & development | $18.0M | $19.7M | −$1.7M | -8% |
| SG&A | $80.7M | $76.1M | $4.6M | +6% |
| Operating cash sources | $36.2M | $26.5M | $9.7M | +37% |
| Depreciation & amortization | $6.8M | $6.4M | $364K | +6% |
| Share-based compensation | $18.2M | $18.9M | −$760K | -4% |
| Working capital & other | $11.2M | $1.1M | $10.1M | +908% |
| Net loss absorbed | $35.1M | $44.0M | −$9.0M | -20% |
| Operating cash flow | $1.1M | −$17.6M | $18.7M | — |
| Capital expenditures | $9.8M | $7.9M | $1.9M | +24% |
| Negative free cash flow (OCF − capex) | $8.6M | $25.4M | −$16.8M | -66% |
Questions
How much did Twist Bioscience's revenue grow quarter over quarter in Q3 FY26?
Twist Bioscience's revenue rose $7.7M (+7%) from $111M in Q2 FY26 to $118M in Q3 FY26.
What drove Twist Bioscience's revenue change in Q3 FY26?
NGS applications +$4.4M (+8%); DNA synthesis and protein solutions +$3.3M (+6%).